Curis company info

What does Curis do?
Curis (NASDAQ:CRIS) focuses on innovating and developing new treatments in the fight against cancer. With a passion for leveraging the latest in molecular and cancer biology to unlock new therapeutic pathways, Curis is dedicated to the discovery and development of groundbreaking drug candidates. The company's projects span various stages of clinical trials, aiming to address some of the most challenging oncological targets. Central to their mission is the objective to provide novel, effective therapies to improve the lives of patients struggling with cancer. By pushing the boundaries of current treatment paradigms, Curis endeavors to make significant contributions to oncology and patient care.
Curis company media
Company Snapshot

Is Curis a public or private company?

key
Ownership
Public

How many people does Curis employ?

people
Employees
49

What sector is Curis in?

pie chart
Sector
Health Care

Where is the head office for Curis?

location pin
Head Office
Lexington, United States

What year was Curis founded?

founded flag
Year Founded
2000
What does Curis specialise in?
/Cancer Therapies /Drug Discovery /Research Services /Clinical Trials /Biotechnology Company /Pharmaceutical Development

What are the products and/or services of Curis?

Overview of Curis offerings
CA-170, a first-in-class oral small molecule targeting PDL1 and VISTA for advanced solid tumors and lymphomas.
CA-4948, an IRAK4 inhibitor aimed at treating patients with non-Hodgkin lymphoma.
Fimepinostat, a dual inhibitor of PI3K and HDAC for the treatment of patients with lymphomas.
CA-327, a first-in-class oral small molecule targeting PDL1 and TIM3 for advanced solid tumors and lymphomas.
Collaboration with Aurigene in the discovery and development of small molecule therapeutics in oncology.

Who is in the executive team of Curis?

Curis leadership team
  • Mr. James E. Dentzer
    Mr. James E. Dentzer
    President, CEO, Secretary, Treasurer & Director
  • Ms. Diantha  Duvall C.P.A., M.B.A.
    Ms. Diantha Duvall C.P.A., M.B.A.
    CFO and Principal Financial & Accounting Officer
  • Mr. Mark W. Noel
    Mr. Mark W. Noel
    Vice President of Technology Management & Intellectual Property
  • Ms. Elif  McDonald
    Ms. Elif McDonald
    VP of Investor Relations & Corporate Communications
  • Dr. Reinhard Wilhelm von Roemeling M.D.
    Dr. Reinhard Wilhelm von Roemeling M.D.
    Senior Vice President of Clinical Development
  • Dr. Jonathan B. Zung Ph.D.
    Dr. Jonathan B. Zung Ph.D.
    Chief Development Officer